Background Antithyroid drugs (ATDs) are first-line treatment for Graves' hyperthyroidism worldwide, but relapses are frequent. The reliability of individual risk factors to predict at baseline subsequent relapse is poor. Predictive scores grouping single risk factors might help to select the best treatment (pharmacological vs. ablative). Objective To assess the predictivity of a recently developed score (Clinical Severity Score, CSS) and to compare it with another score (GREAT score). Patients A retrospective observational, single-center study was conducted of 387 consecutive, newly diagnosed Graves' patients, who completed an 18-24 months ATD course and were followed for at least 2 years. Results Hyperthyroidism relapsed in 185 patients (48%). At diagnosis and before treatment, the relapse group had higher serum TSH-receptor antibody and free thyroxine levels and larger goiters than the remission group, with no differences in Graves' orbitopathy prevalence and severity. In the multivariate analyses, only large goiter size was significantly associated with an increased recurrence hazard ratio. Using CSS, the risk of relapse increased from 36% in the mild category and 49% in the moderate category to 59% in the severe category, with quite a good area under the curve (AUC) (0.60; 95% CI: 0.55; 0.66). GREAT score showed an increase in relapse from 34% for class I (mild) and 49% for class II (moderate) to 64% for class III (severe) (AUC, 0.63; CI: 0.58; 0.68). Conclusions Both CSS and GREAT score are useful, although imperfect, tools to predict at baseline relapse of hyperthyroidism after treatment. In real life they may help the clinician to tailor a treatment for newly diagnosed Graves' hyperthyroidism.
Introduction
Graves' disease (GD) is an autoimmune disorder and the most common cause of hyperthyroidism in iodine-replete areas [1] , with a lifetime risk of about 3% for women and 0.5% for men [2] . Hyperthyroidism is eventually due to production of TSH-receptor autoantibody (TRAb) which stimulates thyroid follicular cells, thereby causing thyroid gland growth and excessive and uncontrolled thyroid hormone synthesis and secretion [2] . Treatment options for Graves' hyperthyroidism include antithyroid drugs (ATDs), radioiodine (RAI) therapy, and thyroidectomy. Recent surveys have confirmed the persistence of geographical differences in the first-line treatment choice for newly diagnosed Graves' hyperthyroidism [1, 3, 4] . In Europe, Asia and Latin America, ATDs represent the first-line treatment; in Northern America, RAI still is the therapy of choice [3, 4] , but recent updates seem to indicate that ATDs are the first-line treatment in USA as well [5] .
The major limitation of ATD treatment is the high relapse rate following drug withdrawal, ranging from 30 to 70% in different series [6] . It would be extremely useful to predict the chances of remission (or the risk of recurrence) already at diagnosis, allowing an early shift to a definitive treatment if the risk of relapse is high. Large goiter size, severe hyperthyroidism, high TRAb values at baseline, and smoking habits seem to be important single risk factors, while the impact of (young) age, gender, and Graves' orbitopathy (GO) is more uncertain [7, 8] . In reality, the predictive value of single risk factors appears to be inadequate to predict the outcome of ATD treatment in an individual patient [8] . Therefore, a combination of single risk factors and the development of related risk scores might help to define an appropriate treatment strategy at diagnosis. Recently, Vos et al. [9] developed the GREAT (Graves' Recurrent Events After Therapy) score, based on goiter size (by palpation), serum free thyroxine (FT4) and TRAb levels, and age at diagnosis. The GREAT score was validated by a Swiss group [10] . We recently developed another score, the Clinical Severity Score (CSS), based on the Merseburg triad [goiter, hyperthyroidism, and GO (exophthalmos)] [11] . The CSS showed a good accuracy in predicting control of hyperthyroidism at 6 and 12 months during ATD therapy [11] .
The aims of this retrospective observational study were to assess the value of the CSS in predicting relapse of hyperthyroidism after an ATD course in a large series of newly diagnosed Graves' patients and to compare it with the GREAT score.
Patients and methods

Study group
The whole group of patients with newly diagnosed Graves' hyperthyroidism referred to our institution between December 2001 and December 2015 included 752 patients. However, 365 patients, whose baseline features did not differ from those of patients included in the present study, were excluded for the following reasons: 125 were still on therapy at the time of analysis; 98 were early shifted to either RAI or thyroidectomy for personal choice or because hyperthyroidism was poorly controlled with ATDs; 22 were lost to follow-up; 120 patients had incomplete data, thus making comparison between CSS and GREAT score not feasible. Therefore, the study group included 387 patients who completed the ATD course and had complete data. The cumulative risk of relapse over follow-up did not differ between patients with missing vs. complete data (log-rank test p value: 0.19).
Diagnosis of Graves' disease was based on established criteria, including positive TRAb tests, suppressed serum TSH levels with increased/normal serum free thyroxine (FT4) levels, diffuse uptake at thyroid scan, hypoechoic ultrasonographic features, or the presence of GO. We included patients diagnosed during pregnancy or postpartum period, as well as patients who developed Graves' hyperthyroidism during amiodarone or interferon therapy. Patients previously treated for hyperthyroidism or with negative tests for TRAb were excluded. After diagnosis, ATD treatment with methimazole in most cases or, less frequently, with PTU was started and continued for 18-24 months using the titration method. The starting daily dose ranged 15-30 mg/day for MMI and 150-300 mg/day for PTU, while the maintenance dose was in most cases 5-10 mg/ day for MMI and 50 mg/day for PTU. During treatment, patients were reevaluated every 6 months until the end of therapy. After ATD withdrawal, they were followed up every 4-6 months for the first year and then annually. Goiter size was assessed by ultrasonography, using the ellipsoid formula. Graves' orbitopathy (GO) was assessed as proposed by the European Group on Graves' Orbitopathy (EUGOGO) [12] . Genetic information was not available.
Approval of the institutional review board or local ethical committee was not deemed necessary because the study was retrospective and did not require additional clinical procedures beyond those done in the delivery of usual care. Data were anonymized.
Assessment of severity of Graves' disease
Severity of Graves' disease at presentation was assessed using two scores: the CSS [11] and the GREAT score [9] ( Table 1) .
The CSS considers the three components of the Merseburg triad (goiter, hyperthyroidism, and GO). For each component, as previously described [11] , we defined four categories: category 1 (serum FT4 within the normal limits; normal thyroid volume; absent GO), category 2 (serum FT4 or thyroid volume ≤ 1.5-fold above the upper normal limit; mild GO), category 3 (serum FT4 or thyroid volume > 1.5 fold but ≤ 2.5 fold above the upper normal limit; moderate-to-severe GO), and category 4 (serum FT4 or thyroid volume > 2.5 fold above the upper normal limit; sightthreatening GO). One point was given for each component to category 1, two points to category 2, four points to category 3, and eight points to category 4. The CSS was the sum of the points given to the three components and could range from 3 to 24. The disease was defined as mild if CSS was between 3 and 5, moderate for scores between 6 and 8, and severe for scores ≥ 9. Thyroid volume was assessed by thyroid ultrasound: normal volume is ≤ 14 ml in women and ≤ 18 ml in men [11] .
The GREAT score considers: patient's age, hyperthyroidism severity, serum FT4 values, TRAb levels, and goiter size by palpation [9] . One point was given for age < 40 years and 0 point for age > 40 years; one point for FT4 levels ≥ 40 pmol/l (≥ 31 pg/ml) and 0 point for FT4 levels < 40 pmol/l (< 31 pg/ml); one point for TRAb levels ranging 6-19.9 U/l, two points for TRAb levels ≥ 20 U/l, and 0 point for TRAb level < 6 U/l; two points for category 2-3 of WHO classification criteria for assessing thyroid volume by palpation and 0 point for category 0-1 [9] . The GREAT score was the sum of the points given to each components and could range from 0 to 6. The disease was defined as mild if GREAT score was between 0 and 1 (class I), moderate for scores between 2 and 3 (class II), and severe for scores between 4 and 6 (class III).
Laboratory measurements
Serum TSH and FT4 were measured by specific RIAs (Liason ® Dia Sorin). Reference ranges are: TSH, 0.31-5 μU/ ml; FT4, 7.8-18 pg/ml. Serum TRAb levels were measured by second-generation radioreceptor assay (Thermo Fisher, Germany); thyroid peroxidase antibody (TPOAb) was assayed by solid-phase RIA (Thermo Fisher, Germany). Normal values for TRAb and TPOAb are < 1 U/l and < 60 U/ml, respectively.
Statistical analysis
Baseline demographic features and biochemical and Merseburg triad parameters of the study patients were summarized using descriptive statistics, in the overall case series as well as according to relapse status during follow-up (remission vs. relapse). We tested the null hypothesis of no association between these features and relapse using Chi square, Student's t, and Wilcoxon rank tests for discrete, continuous, and skewed continuous variables, respectively. The cumulative risk of relapse during follow-up was estimated using the Kaplan-Meier approach, to consider censorship. We estimated univariate and multivariate hazard ratios (HRs) with 95% confidence intervals (CI) of relapse for the individual components of the Clinical Severity Score, using Cox proportional hazards regression models. The HRs for the GREAT score and CSS were also estimated from univariate Cox models, with class I as reference. Discrimination ability for the GREAT score and the CSS was estimated using the area under the ROC curve (AUC), which can be interpreted as the probability that individuals who relapse have a larger score than individuals who do not relapse. THE AUC ranges from 0.5 to 1, and a higher score indicates greater discrimination. We estimated AUC and its 95% confidence interval from logistic models with GREAT (CSS) as the only independent variable. We used SAS release 9.4 for statistical analyses, and R version 3.2.5 to draw the cumulative risk picture.
Results
As illustrated in Table 2 , relapse of hyperthyroidism after ATD withdrawal occurred in 185 of 387 patients (48%) after a median follow-up of 8 months; recurrence of hyperthyroidism was observed in 160 of 185 patients (86%) within 1 year after drug discontinuation (Fig. 1) . Baseline features in the whole group and in the subgroups (remission, relapse) are shown in Table 2 . The relapse group had significantly higher median serum TRAb levels and a slightly longer treatment duration than the remission group. The duration of disease was very short and superimposable in both groups. The prevalence of smokers, age, and gender did not differ between the two subgroups ( Table 2) . Table 3 shows that at diagnosis almost half of the patients had a normal thyroid volume and almost one-third had a small goiter, whereas large goiters were observed in a small minority (6%) of patients. Thyroid volume was significantly higher in the relapse group (Table 3) . Based on serum FT4 concentrations, hyperthyroidism was subclinical or mild in more than 40% of cases, whereas only about 20% of patients had severe hyperthyroidism (FT4 > 44 pg/ml) at diagnosis (Table 3) . Severe hyperthyroidism was significantly more frequent in the relapse group than in the remission group (25 vs. 14%). More than three-fourths of patients had no GO at diagnosis, with no differences between the relapse group and the remission groups (Table 3) .
In univariate analyses larger goiter size (> 2.5 fold above normal) and very high serum FT4 levels (> 44 pg/ml) were associated with higher recurrence rates, whereas no association was found between GO and relapse of hyperthyroidism (Table 4 ). The multivariate analyses showed that only larger goiter size was significantly associated with an increased risk of relapse after ATD discontinuation ( Table 4) .
As illustrated in Fig. 2 and Table 5 , both the CSS and the GREAT score showed a homogeneous distribution of patients in the mild (class I in the GREAT score), moderate (class II in the Great score), and severe (class III in the GREAT score) classes of severity of Graves' disease, although the CSS tended to classify a slightly lower proportion of patients as having severe Graves' disease. Figure 3 shows that the risk of relapses progressively increased with the increase in severity of the disease using either score. Using the CSS, the risk of relapse increased from 36% for mild disease to 59% for severe disease. Patients in the severe category had an HR for relapse of 1.98 (95% CI 1.37; 2.85). The CSS showed a fairly good discrimination, with an AUC of 0.60 (95% CI: 0.55; 0.66) ( Table 5 ). Using the GREAT score, the proportion of relapses increased from 34% in patients with class I (mild) disease to 64% in patients with class III (severe) disease. As shown in Table 5 , the HR of relapses was 2.21 (95% CI: 1.51; 3.24), and discrimination was fairly good with an AUC of 0.63 (95% CI: 0.58; 0.68).
Discussion
Management of Graves' hyperthyroidism is presently unsatisfactory, because treatments capable of targeting the pathogenetic mechanisms of the disease are missing. Accordingly, a large majority of patients eventually need to be made hypothyroid be either RAI or thyroidectomy. In other words, to cure one disease (hyperthyroidism), we create a second disease (hypothyroidism). The pharmacological approach based on the use of ATDs (thionamides) in most cases adequately controls thyroid hyperfunction, mainly by inhibiting thyroid peroxidase-mediated thyroid hormone synthesis, but often does not induce a permanent remission of the disease [6] , with hyperthyroidism usually relapsing within 1 year following ATD withdrawal [13] .
The results of the present study are in agreement with the data in the literature, since recurrence of hyperthyroidism occurred in about half of the patients, mostly within a few months. In the present series, high TRAb levels and large goiters at diagnosis were associated with an increased risk of relapse, as reported in the literature [13] , but at variance with previous studies [13, 14] we failed to observe an association between young age or smoking habits and the relapse of hyperthyroidism. Conflicting results are frequent in clinical studies, due to selection bias, retrospective features of most studies, and lack of standardized assessment (see, for example, assessment of thyroid size by palpation vs. ultrasonography). Thus, in general, single risk factors at diagnosis lack a sufficient and reliable predictivity regarding the outcome of medical treatment. Looking at the half-full glass, one might argue that 30-70% of Graves' patients may go into remission after completing a course of ATD therapy. If the overall risk could be quantified at diagnosis, this would help the physician and the patient to select, within a shared decisionmaking process, the most appropriate treatment from the very beginning. Should the risk of relapse after a course of ATDs appear very high, a definitive treatment by RAI or thyroidectomy might be proposed after the initial control of hyperthyroidism by ATDs. Conversely, in patients with a low overall risk of relapse, it would be conceivable to plan a full course of ATD therapy with a reasonable expectation to achieve a permanent remission of hyperthyroidism afterward. To this purpose, development of predictive scores that are composed of individual risk factors, each given a score, might increase the discrimination ability of the single risk factors.
The main aim of our study was to evaluate the performance of two recently developed scores in predicting at baseline the relapse of hyperthyroidism after ATDs discontinuation. The first score (GREAT score) was developed by Vos et al [9] , with an external validation by a Swiss group [10] . This score includes the following parameters: age, serum FT4, serum TRAb, and goiter by palpation. By assigning predetermined points to each item, three categories (I = mild, II = moderate, and III = severe) can be identified (Table 1 ). The second score (CSS) was developed by our group and considers thyroid volume by ultrasound, serum FT4 levels, and GO [11] . By classifying each item as absent, mild, moderate, or severe and assigning predefined scores, the overall severity of Graves' disease can be categorized as mild, moderate, or severe (Table 1 ). This score is based on the classical Merseburg triad. The main difference between the two scores is that the CSS does not include TRAb levels, based on the assumption that TRAb is responsible for goiter, hyperthyroidism, and GO. In a previous study, the CSS proved to be effective in predicting the control of hyperthyroidism at 6 and 12 months of therapy, because patients with a high CSS at baseline were more likely to have a poor control of thyroid hyperfunction [11] . The results of the present study showed that a low CSS (mild disease) was associated with 36% cumulative risk of relapse during follow-up, while the risk of relapse increased to 50 and 59% if the CSS was moderate or high, respectively. In our hands, the GREAT score provided similar results, with a slightly better discrimination of the risk of relapse between the moderate and severe scores. Interestingly, the risk of relapse in class I (34%) was exactly the same as that observed in the validation study by Struja et al. [10] , but much higher than that (16%) reported in the original study by Vos et al. [9] . This difference is unexplained. Thus, both scores, although developed with different constitutive markers, showed good performance. Neither score is perfect because 35-40% of patients with a high score (either CSS or GREAT) will remain in remission, whereas about one-third of those with low scores using either CSS or the GREAT score will eventually relapse. However, the possibility of discriminating at diagnosis between patients at 30 or 60% risk of long-term remission after a course of ATD treatment is not trivial, can make a difference, and may orient from the very beginning the therapeutic strategy toward a definitive treatment in the first case or long-term pharmacological therapy in the second case.
In conclusion, both the CSS and the GREAT score, although based on slightly different premises, may be of help in planning the treatment strategy in a given patient with newly diagnosed Graves' hyperthyroidism in real life. Both scores might be further improved by including additional factors, thereby enhancing discrimination between relapsing patients and remitting patients.
